A clinical study to evaluate the effect of Siddha Medicine Kadalazhinjil Kudineer in Early Diabetic Kidney Disease

Single centric Phase II open clinical trial in management of Surari Megam (Diabetic Microalbuminuria) with the siddha medicine Kadalazhinjil Kudineer - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105476

Enrollment

Registered

2026-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E132- Other specified diabetes mellituswith kidney complications

Interventions

Intervention1: KADALAZHINJIL KUDINEER: Kadalazhinjil pattai (salacia reticulata) BALAM (8.75g) Purified Kadalazhinjil bark will be grinded into coarse powder and stored in container. The powder wi

Eligibility

Inclusion criteria

Inclusion criteria: Known type 2 Diabetic patients with urine albumin ranging 30-300mg in spot urine sample. UACR: 30-300 mg HbA1C greaterthan or equalto 8 percentage

Exclusion criteria

Exclusion criteria: Patients with other severe complications of DM K/C/O Type I Diabetes K/C/O Hypertension Vulnerable population Anyother systemic illness/infections Use of Nephrotoxic Medications

Design outcomes

Primary

Measure	Time frame
The outcome will be mainly assessed by reduction in URINE MICROALBUMINURIA, URINE ALBUMIN TO CREATININE RATIO (UACR)Timepoint: The outcome will be mainly assessed by reduction in URINE MICROALBUMINURIA, URINE ALBUMIN TO CREATININE RATIO (UACR) in 12 weeks	—

Secondary

Measure	Time frame
Reduction in HbA1C level by 1. 20 percentage Good 2. 10 percentage Fair 3. less than 10 percentage -PoorTimepoint: 90 days	—

Countries

India

Contacts

Public ContactDr R Menaka

Government Siddha Medical College, Chennai

rangasamymenaka75@gmail.com9444669661

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026